Positioning NK Receptor Antagonism in the Vasomotor Symptoms Treatment Landscape

This discussion situates NK receptor antagonists within the evolving treatment hierarchy for menopause. Fezolinetant’s approval and elinzanetant’s pending review introduce options that complement rather than replace hormone therapy, expanding clinicians’ ability to individualize care.

Panelists emphasize patient selection—considering comorbidities, contraindications, and preferences—as critical to optimizing outcomes. Those ineligible for hormones or seeking nonhormonal solutions may particularly benefit from these agents.

The segment underscores that integrating these treatments thoughtfully can modernize menopause management, balancing efficacy, safety, and accessibility.